BioAge Labs (BIOA) Share-based Compensation (2023 - 2026)
BioAge Labs' (BIOA) quarterly Share-based Compensation came in at $9.2 million in Q2 2026, up 13.74% year-over-year from $8.0 million in Q2 2025, and down 1.48% quarter-over-quarter from $9.3 million in Q1 2026.
Analysis
BioAge Labs (BIOA) Share-based Compensation (2023 - 2026) Analysis & Trends
BioAge Labs has disclosed Share-based Compensation across 4 years of filings, most recently posting $9.2 million for Q2 2026.
- In Q2 2026, Share-based Compensation rose 13.74% year-over-year to $9.2 million; the TTM figure through Jun 2026 stood at $9.2 million (up 13.74% YoY), while the FY2025 annual figure was $23.8 million, down 9.85% from the prior year.
- Share-based Compensation came in at $9.2 million for Q2 2026 at BioAge Labs, down from $9.3 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $9.3 million in Q1 2026 to a low of $757000.0 in Q3 2023.
- Average Share-based Compensation over 4 years is $4.8 million, with a median of $4.0 million recorded in 2024.
- The largest YoY upside for Share-based Compensation was 836.0% in 2025 against a maximum downside of 0.04% in 2025.
- Over 4 years, Share-based Compensation stood at $767000.0 in 2023, then soared by 254.76% to $2.7 million in 2024, then advanced by 0.04% to $2.7 million in 2025, then jumped by 236.29% to $9.2 million in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $9.2 million in Q2 2026, $9.3 million in Q1 2026, and $2.7 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 209.77 Bn | 195.78 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 180.17 Bn | 176.99 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 131.81 Bn | 123.96 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 82.07 Bn | 74.07 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 61.31 Bn | 56.12 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.58 Bn | 48.44 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.65 Bn | 30.34 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.73 Bn | 30.44 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 29.65 Bn | 29.65 Bn | 1.16 Mn | 83.34 Mn |
| 10 | BioAge Labs | 400.41 Mn | 400.41 Mn | -14.23 Mn | 9.15 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.15 Mn |
| Mar 31, 2026 | 9.29 Mn |
| Dec 31, 2025 | 2.72 Mn |
| Sep 30, 2025 | 8.11 Mn |
| Jun 30, 2025 | 8.05 Mn |
| Mar 31, 2025 | 7.97 Mn |
| Dec 31, 2024 | 2.72 Mn |
| Sep 30, 2024 | 5.25 Mn |
| Jun 30, 2024 | 1.56 Mn |
| Mar 31, 2024 | 852,000.00 |
| Dec 31, 2023 | 767,000.00 |
| Sep 30, 2023 | 757,000.00 |